Academic Journal
Q1Clinical Genitourinary Cancer
About Clinical Genitourinary Cancer
Clinical Genitourinary Cancer is a scholarly journal published by Elsevier Inc.. SCImago 2025 lists it in Q1, with an SJR of 1.05 and H-index of 62.
Coverage: 2005-2026. Research categories: Urology (Q1); Oncology (Q2).
Journal Metrics
Metrics can change by reporting year. Verify time-sensitive values with the publisher or indexing service.
Aims & Scope
Scope information will be added after verification.
Recent Research Articles
Latest publications matched automatically by ISSN.
The Utility of the Comprehensive Complication Index in Demonstrating the Complication Burden and Predicting Length of Stay in Robot-Assisted Radical Prostatectomy
Yunus Çolakoğlu, Deniz Noyan Özlü, Büşra Emir, Enes Yavuz et al.
2026-12 · DOI: 10.1016/j.clgc.2026.102659Impact of Age on Outcomes in Metastatic Non–Clear Cell Renal Cell Carcinoma: A Real-World TriNetX Analysis From the Global Society of Rare Genitourinary Tumors (GSRGT)
Antonio Cigliola, Nazli Dizman, Chiara Mercinelli, Yao Zhu et al.
2026-12 · DOI: 10.1016/j.clgc.2026.102658Real-World Treatment Duration With First-line Enfortumab Vedotin Plus Pembrolizumab for Advanced Urothelial Cancer: A National Electronic Health Record Study
Melanie Mayer, Nicholas J. Seewald, Ernesto Ulloa-Pérez, Blanca Homet Moreno et al.
2026-12 · DOI: 10.1016/j.clgc.2026.102652Efficacy and Safety of Every Other Week Gemcitabine and Docetaxel (GEMDOC) in Heavily Pretreated Metastatic Castration Resistant Prostate Cancer: A Retrospective Real-world Analysis
Jordan Ciuro, Ahmet Yildirim, Yuan Liu, Angelo Marra et al.
2026-12 · DOI: 10.1016/j.clgc.2026.102657Impact of Gleason Grade at the Positive Surgical Margin on Biochemical Recurrence After Radical Prostatectomy in pT2N0 Prostate Cancer
Mehdi Kardoust Parizi, Akihiro Matsukawa, Ichiro Tsuboi, Pawel Rajwa et al.
2026-12 · DOI: 10.1016/j.clgc.2026.102648Immunophenotyping and Molecular Patterns of Prostate Cancer in East Africa: Diagnostic and Prognostic Implications—A Systematic Review
Charles Malisaba Posite, Henry Wabinga, Raymond Atwine, Bienfait Mumbere Vahwere et al.
2026-10 · DOI: 10.1016/j.clgc.2026.102637Why Has Prostate Cancer Research Lagged Behind? Advocacy, Biology, and the Road Ahead
Gabriel Victor Pimentel Silva, Marvin Paulo Lins
2026-10 · DOI: 10.1016/j.clgc.2026.102643Utility of Circulating Tumor DNA as a Monitoring Tool for Marker-Negative Germ Cell Tumors and Somatic Type Malignancies
Zachariah Thomas, Michael Glover, Andrew C. Johns, Emanuele Crupi et al.
2026-10 · DOI: 10.1016/j.clgc.2026.102650Real-World Effectiveness and Tolerability of Belzutifan in Sporadic Clear Cell Renal Cell Carcinoma: A Retrospective Cohort Study With Exploratory Genomic Correlation
Parker Mathews, Hannah Neiditz, Phoenix Hollenbeck, Jeevan Rajkumar et al.
2026-10 · DOI: 10.1016/j.clgc.2026.102645Timing of Second-Line Nivolumab and Survival in Metastatic Renal Cell Carcinoma
Uğur Özberk, Fahriye Tuğba Köş, Perihan Perkin, Öznur Bal et al.
2026-10 · DOI: 10.1016/j.clgc.2026.102653Age at Diagnosis and Postoperative Outcomes Among Men Treated for Prostate Cancer in the U.S. Military Health System
Molly R. Oroho, Christian Dide-Agossou, Sean Q. Kern, Andrea A. Almeida et al.
2026-10 · DOI: 10.1016/j.clgc.2026.102632PARP Inhibitor Plus Androgen-receptor Signaling Inhibitor Versus the Same Inhibitor Alone in Homologous-Recombination-Repair-Altered Metastatic Prostate Cancer Across the Hormone-Sensitive and Castration-Resistant Continuum: A Systematic Review and Meta-Analysis
Yanfeng Su, Ruji Wu, Huien Pan, Haofeng Yuan et al.
2026-10 · DOI: 10.1016/j.clgc.2026.102629Early Achievement of Ultra-low PSA Levels Correlates With Prolonged Radiologic Progression-free Survival (rPFS) in Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Deniz Tural, Fatih Kemik, Caner Kapar, Cevat İlteriş Kıkılı et al.
2026-10 · DOI: 10.1016/j.clgc.2026.102647Evaluating Circulating DNA as a Prognostic Biomarker in Bladder Cancer Subtypes: A Preliminary Short Report
Adri M. Durant, Jacob Steffen, Heather Huelster, Hristos Kaimakliotis et al.
2026-10 · DOI: 10.1016/j.clgc.2026.102635Association Between Enfortumab Vedotin-Related Adverse Events and Clinical Outcomes in Advanced Urothelial Carcinoma: A Systematic Review and Meta-Analysis
Akimasa Sanagawa, Hideo Kato, Takahiro Inoue, Takuya Iwamoto et al.
2026-10 · DOI: 10.1016/j.clgc.2026.102617Nomograms for Predicting Recurrence and Oncologic Outcomes After Partial Nephrectomy for Renal Cell Carcinoma
Vinícius Luiz Menezes Jesus, Gabriel Carvalho dos Anjos, Gabriel Kledeglau Jahchan Alves, Edgar Alexandre Aviles Sandoval et al.
2026-10 · DOI: 10.1016/j.clgc.2026.102634Risk Factors and Treatment Outcomes in Metastatic Prostate Cancer With Brain Metastases
Vincent E. Xu, Jeffrey Wang, Rachel C. Bernardo, Michelle Wang et al.
2026-10 · DOI: 10.1016/j.clgc.2026.102600Prognostic Value of Androgen Receptor (AR) Gene Alterations Detected in Circulating Tumor DNA (ctDNA) in Patients With Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-analysis
Mingrui Huang, Jiahui Yang, Heng Guo, Cong Huang et al.
2026-10 · DOI: 10.1016/j.clgc.2026.102651Patterns of Poly(ADP-Ribose) Polymerase Inhibitor Use and Overall Survival in United States Veterans With Prostate Cancer
Rhonda L. Bitting, Chin-lin Tseng, Alexandros Giagtzis, Alexander W. Wyatt et al.
2026-10 · DOI: 10.1016/j.clgc.2026.102640Sex-Specific Differences in Disease-Free, Progression-Free and Overall Survival Following Enfortumab Vedotin Therapy for Advanced or Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis
Laila Schneidewind, Jennifer Kranz, Friedemann Zengerling, Thomas Neumann et al.
2026-10 · DOI: 10.1016/j.clgc.2026.102611Reviews
Community Reviews
Version History
September 25, 2026 at 7:56 am
September 25, 2026